Cetyl myristoleate
| |
| Names | |
|---|---|
| IUPAC name
Hexadecyl (Z)-tetradec-9-enoate
| |
| Other names
cis-9-Cetyl myristoleate
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChemSpider | |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C30H58O2 | |
| Molar mass | 450.792 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Cetyl myristoleate is a chemical compound which is a type of fatty acid ester or, more specifically, a cetylated fatty acid (CFA). It is the cetyl ester of myristoleic acid. Although it is used as a dietary supplement, there is little clinical evidence to support a benefit for any medical condition.[1]
Synthesis
Cetyl myristoleate has been prepared by an esterification reaction between myristoleic acid and cetyl alcohol, catalyzed by p-toluenesulfonic acid monohydrate.[2]
Animal pharmacology
In animal studies, cetyl myristoleate was first reported to block inflammation and prevent adjuvant-induced arthritis at very high doses in rats.[2][3] Other studies using identical and similar methods have failed to replicate this effect.[4] In follow-up studies in mice, a modest anti-inflammatory effect was observed.[2]
Study in humans
Although cetyl myristoleate is sold as a dietary supplement, its possible benefits in the treatment of any medical condition are largely unknown[1] and the Federal Trade Commission has taken legal action against supplement manufacturers for exaggerated claims.[5]
There is some clinical evidence for the benefits of CFAs, which may contain cetyl myristoleate, in arthritic patients.[6] One pilot study found that cetyl myristoleate may be beneficial against fibromyalgia.[7] However, these low-quality clinical trials provide only limited scientific evidence of efficacy.[1]
References
- ^ a b c Ameye, Laurent G; Chee, Winnie SS (2006). "From nutraceuticals to functional foods". Arthritis Research & Therapy. 8 (4): R127. doi:10.1186/ar2016.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ a b c Hunter, Kenneth W; Gault, Ruth A; Stehouwer, Jeffrey S; Tam-Chang, Suk-Wah (2003). "Synthesis of cetyl myristoleate and evaluation of its therapeutic efficacy in a murine model of collagen-induced arthritis". Pharmacological Research. 47 (1): 43–7. doi:10.1016/S1043-6618(02)00239-6. PMID 12526860.
- ^ H.W Diehl, E.L May (1994). "Cetyl myristoleate isolated from Swiss albino mice: an apparent protective agent against adjuvant arthritis in rats". J Pharm Sci. 83 (3): 296–9. doi:10.1002/jps.2600830307. PMID 8207671.
- ^ Whitehouse, MW; McGeary, RP (1999). "Concerning the anti-arthritic action of cetyl myristoleate in rats: An interim report". Inflammopharmacology. 7 (3): 303–10. doi:10.1007/s10787-999-0014-z. PMID 17638102.
- ^ See for example:
• DOCKET NO. C-3896, Federal Trade Commission
• FTC Complaint against EHP Products, Inc.
• FTP Complaint against CMO Distribution Centers of America, Inc. - ^ Hesslink Jr, R; Armstrong d, 3rd; Nagendran, MV; Sreevatsan, S; Barathur, R (2002). "Cetylated fatty acids improve knee function in patients with osteoarthritis". The Journal of rheumatology. 29 (8): 1708–12. PMID 12180734.
{{cite journal}}: CS1 maint: numeric names: authors list (link) - ^ A.M Edwards (2001). "CMO (cerasomol-cis-9-cetyl myristoleate) in the treatment of fibromyalgia: an open pilot study". J. Nutr. Environ. Med. 11 (2): 105–111. doi:10.1080/13590840120060849.